Levetiracetam Actavis

Pays: Nouvelle-Zélande

Langue: anglais

Source: Medsafe (Medicines Safety Authority)

Ingrédients actifs:

Levetiracetam 500mg;  

Disponible depuis:

Teva Pharma (New Zealand) Limited

DCI (Dénomination commune internationale):

Levetiracetam 500 mg

Dosage:

500 mg

forme pharmaceutique:

Film coated tablet

Composition:

Active: Levetiracetam 500mg   Excipient: Colloidal silicon dioxide Crospovidone Magnesium stearate Opadry yellow 85F32371 Povidone

Type d'ordonnance:

Prescription

Fabriqué par:

Neuland Laboratories Limited

indications thérapeutiques:

Use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. Monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. Add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME). Add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (IGE).

Descriptif du produit:

Package - Contents - Shelf Life: Blister pack, PVC/Al - 60 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE with LDPE screw cap and tamper evident - 100 tablets - 36 months from date of manufacture stored at or below 25°C

Date de l'autorisation:

2015-01-22